Opendata, web and dolomites

Safe-Blood SIGNED

A cost and time effective blood test to detect multiple bloodborne diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Safe-Blood project word cloud

Explore the words cloud of the Safe-Blood project. It provides you a very rough idea of what is the project "Safe-Blood" about.

time    supply    alone    hiv    hepatitis    carries    annually    swiss    screened    save    solely    400    15    htlv    diagnose    tests    simultaneously    safe    model    wama    business    reducing    equal    founded    diseases    stakeholder    global    smei    competition    2015    risk    benefit    preliminary    infections    transmit    players    thousands    donation    screen       blood    engagement    lives    laboratory    position    demonstrates    threatening    donations    donor    multiple    multiplex    chagas    sufficient    compound    affordable    collected    banks    vitro    disease    questionnaire    collection    single    money    billion    grow    transmitted    struggle    life    hold    convert    screening    union    excluded    expertise    donors    annual    involvement    subsequently    carriers    prevent    reduce    feasibility    transfusion    diagnostics    million    2024    rate    continuous    market    infectious    syphilis    ambition    company    disrupt    250    monoplex    commercial    responsible   

Project "Safe-Blood" data sheet

The following table provides information about the project.

Coordinator
WAMA DIAGNOSTICS (SWITZERLAND) SA 

Organization address
address: ROUTE DE L'ILE-AU-BOIS 1A
city: MONTHEY
postcode: 1870
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.wamadiagnostics.ch/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2019-02-28

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WAMA DIAGNOSTICS (SWITZERLAND) SA CH (MONTHEY) coordinator 50˙000.00

Map

 Project objective

In the European Union alone, 15 million blood donations are collected annually, but supply of sufficient and safe donor blood remains a continuous struggle. Blood can save lives; however, it also carries the potential to transmit life-threatening infections. Potential donors are screened using a questionnaire aimed to identify risk carriers. As risk carriers do not equal disease carriers, thousands of potential donors are excluded to prevent one single case of a transfusion-transmitted disease. Subsequently, blood donations are screened for infectious diseases in the laboratory with one test for each disease.

WAMA Diagnostics is a Swiss-founded company with the ambition to disrupt the in vitro diagnostics market with affordable and reliable tests to diagnose infectious diseases. WAMA has the expertise and technology to convert multiple tests into one single test, reducing time and money. WAMA is developing the Safe-Blood test to simultaneously screen for HIV, Hepatitis B, Hepatitis C, Syphilis, HTLV and Chagas in a single test. Our preliminary cost-benefit analysis demonstrates the potential to reduce the screening costs from €70 - €250 per donor to €15 per donor.

1,400 European blood donation banks are responsible for the collection of the 15 million blood donations per year. The global blood screening market is expected to grow from €1.3 billion in 2015 with a Compound Annual Growth Rate of 10.2% to €3.1 billion in 2024. The competition is offering solely monoplex tests: one test for one disease. There are currently no players on the blood screening market that use multiplex tests to screen for multiple diseases simultaneously, and the Safe-Blood test will hold a unique position in the market.

WAMA will use the SMEi phase 1 funding to assess the feasibility and commercial potential of Safe-Blood via a user involvement study, a stakeholder engagement study, and a market study to identify the best business model to be applied in the EU.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAFE-BLOOD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAFE-BLOOD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

SQP (2019)

Opening new markets for Single Quantum Photodetectors

Read More